SAN DIEGO, Nov. 25, 2015 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of patients with cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the LD Micro Main Event on Thursday, December 3, 2015 at 12:00 p.m. Pacific time. The conference is being held at Luxe Sunset Boulevard Hotel in Los Angeles.
A live webcast of the presentation will be available on the investor relations page of the Company's corporate website at ir.biocept.com. A replay of the presentation will be available for 90 days.
Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated tests for other solid tumors in the near term. For additional information, please visit www.biocept.com.
SOURCE Biocept, Inc.